Displaying items by tag: healthcare
Healthcare technology is a rapidly changing field that has a plethora of new ideas entering the market daily, but driving that change is impact investing. The Covid-19 pandemic laid bare many of the problems in the healthcare sector and health technology is closing many of those gaps. For example, Zipline used fleets of drones to distribute vaccines to out of reach populations around the globe after securing $250 million in funding. Healthcare is the third-largest portion of impact investing, lagging climate and financial services, but it’s the fastest-growing area. Venture capital in healthcare doubled in 2020 from 2019, and many see this capital as augmenting government and charitable giving to healthcare to improve access and distribution. Breakthroughs in the sector include companies like Han Genix, which uses ultrasound technology to ensure safety procedures are followed by medical workers, or Plethy which syncs sensors and apps to improve post-orthopedic care.
FINSUM: Technology healthcare blends could become one of the best ways to capture growth and industry diversity in your portfolio.
Here is a tough fact for clients to accept: the major of retirees will need long-term care as they age. From an emotional perspective, that is difficult to expect. From a financial perspective, it is even worse. The average cost of long-term care is between $53,000 to $105,000 per year. This presents a major funding challenge for retirees.
FINSUM: Advisors need to help clients come to terms with this likelihood. Long-term care insurance is a good option for this situation. This usually costs between $1,375 to $3,600 a year for a 55 year-old man, and between $2,150 and $6,4000 for a 55 year-old woman.
The recent market turmoil has made some investors skittish over what to do in the stock market. But…see the full story on our partner Magnifi’s site
Many of the major players in Biotechnology are seeing their stocks soar…see the full story on our partner Magnifi’s site
Healthcare has been one of the predominant stories of the pandemic, but its stock prices…see the full story on our partner Magnifi’s site